RLX

Fifty-two postmenopausal women with moderate to severe hot flushes were randomized to receive either 60 mg raloxifene (RLX; n=20), 0.5 mg percutaneous 17β-estradiol associated to 60 mg raloxifene (RLX+E2; n=16) or placebo (PLC; n=16).

2009 January 20, Beatriz Valiati; Edison Capp, Maria Isabel Edelweiss; Fernando Monteiro de Freitas; Maria Celeste Osório Wender, “Effect of raloxifene and low-dose percutaneous 17β-estradiol on menopause symptoms and endometrium--a randomized controlled trial”, in Maturitas, 1 edition, volume 62, →DOI, →PMID, page 81 of 81–84